Platelets, Microenvironment and Hepatocellular Carcinoma
- *Corresponding Author:
- Brian I. Carr
Izmir International Biomedicine and Genome Institute
Dokuz Eylul University, 35340 Balçova
Tel: +90 232 4121212
E-mail: [email protected]
Received date: Mar 18, 2016; Accepted date: June 25, 2016; Published date: June 29, 2016
Citation: Yilmaz Y, Erdal E, Atabey N, Carr BI (2016) Platelets, Microenvironment and Hepatocellular Carcinoma. Biochem Anal Biochem 5: 281. doi:10.4172/2161-1009.1000281
Copyright: © 2016 YÄ±lmaz Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hepatocellular carcinoma (HCC) is the commonest type of liver cancer and has a high mortality rate. Currently treatment options are limited and new therapies are urgently needed. Platelets are enucleated small cells, derived from mature megakaryocytes and besides their role in thrombosis; they actively take part in carcinogenesis and metastasis. Platelet number in the blood is associated with disease progression, overall survival and HCC subgrouping. Both thrombocytosis and thrombocytopenia are associated with HCC phenotype and size, related with other factors like cirrhosis background. Platelet counts and also platelet-to-lymphocyte ratio (PLR) and neutrophil-tolymphocyte ratio (NLR) are considered in decision making in management. Since platelets also take up nucleotides and cytokines from tumor cells, isolating and studying platelets might provide valuable information for understanding tumor cells and may help to develop personalized treatment. Anticoagulants and antiplatelet agents are commonly used potential cancer therapeutics, which are also being studied for HCC treatment. Thus, platelets are one aspect of a complex microenvironmental milieu, the affects the biology of HCC and other tumors.